vTv Therapeutics(VTVT) - 2024 Q2 - Quarterly Report

Regulatory Updates - The FDA placed a clinical hold on the cadisegliatin clinical program, including the ongoing CATT1 Phase 3 trial for type 1 diabetes, due to unresolved chromatographic signals in a recent study[76]. - Cadisegliatin received Breakthrough Therapy designation from the FDA in 2021, supported by positive results from the Phase 2 SimpliciT-1 Study, which showed a 40% reduction in severe hypoglycemia[79]. Financial Performance - The company reported no revenue for the three months ended June 30, 2024, consistent with the same period in 2023[90]. - Revenue for the six months ended June 30, 2024, was $1.0 million, an increase due to the satisfaction of a development milestone under the Newsoara License Agreement[96]. - The net loss attributable to vTv Therapeutics Inc. for Q2 2024 was$5.2 million, a decrease of $0.4 million from a net loss of$5.6 million in Q2 2023[89]. - Total operating expenses for Q2 2024 were $7.2 million, a decrease of$0.8 million from $8.0 million in Q2 2023[89]. - Net cash used in operating activities increased to$(14.1) million for the six months ended June 30, 2024, compared to $(11.3) million in 2023[105]. - Net cash provided by financing activities was$50.1 million for the six months ended June 30, 2024, significantly higher than $11.8 million in 2023[104]. - As of June 30, 2024, the company had cash and cash equivalents of$45.5 million and an accumulated deficit of $291.3 million[102]. - The company has not generated any revenue from drug product sales and does not expect to until regulatory approval is obtained[106]. Research and Development - Research and development expenses for Q2 2024 were$3.4 million, a decrease of $1.3 million or 26.7$4.7 million in Q2 2023, primarily due to lower spending on cadisegliatin[91]. - Research and development expenses decreased by $2.5 million, or 29.5$6.1 million for the six months ended June 30, 2024, primarily due to lower spending on cadisegliatin[97]. - The company plans to initiate two international registrational studies for cadisegliatin in type 1 diabetes, expected to start in 2026[79]. - The company continues to work with G42 Investments to initiate a Phase 2 trial in the Middle East for type 2 diabetes, expected to begin in 2024[79]. Administrative Expenses - General and administrative expenses increased to $3.7 million in Q2 2024, up$0.4 million or 12.3% from $3.3 million in Q2 2023, driven by higher share-based expenses and legal costs[92]. - General and administrative expenses increased by$0.9 million, or 13.2%, to $7.7 million for the six months ended June 30, 2024, driven by higher payroll and legal expenses[98]. Interest Income - Interest income for Q2 2024 was$0.6 million, compared to $0.2 million in Q2 2023, primarily from dividends and interest from money market accounts[93]. - Interest income for the six months ended June 30, 2024, was$0.6 million, up from $0.3 million in the same period of 2023[99]. Financial Strategy and Risk Management - The company anticipates needing substantial additional funding to continue operations and clinical trials[106]. - The company closed a private placement financing of up to$51.0 million on February 27, 2024, to advance its lead program for cadisegliatin[102]. - The company has no material interest rate exposure, indicating a stable financial position regarding interest rates[111]. - The exposure to market risk is limited to cash and cash equivalents, all with maturities of one year or less[112]. - The investment strategy focuses on capital preservation, liquidity fulfillment, and fiduciary control of cash and investments[112]. - The company aims to maximize income from investments without assuming significant risk[112]. - There is no material foreign currency exposure, suggesting minimal risk from currency fluctuations[113].